OPEN ACCESS

Saudi Journal of Pathology and Microbiology

Abbreviated Key Title: Saudi J Pathol Microbiol
ISSN 2518-3362 (Print) |ISSN 2518-3370 (Online)
Scholars Middle East Publishers, Dubai, United Arab Emirates
Journal homepage: https://saudijournals.com

Original Research Article

Precision-Based Management of Chronic Hair Fall: A Genomic-Guided Trichology Approach - A Case Analysis from Qatar

Dr. Nada Ahmed Al-Mulla, M.D[1]*

[1]Doctor of Medicine Independent Researcher Doha, Qatar

DOI: https://doi.org/10.36348/sjpm.2026.v11i02.001 | **Received:** 08.01.2026 | **Accepted:** 04.03.2026 | **Published:** 06.03.2026

***Corresponding author:** Dr. Nada Ahmed Al-Mulla
Doctor of Medicine Independent Researcher Doha, Qatar

Abstract

Hair loss in women represents a complex clinical challenge with profound psychosocial implications. We present the case of a young woman from Qatar who experienced severe diffuse hair fall for three years despite consulting eight dermatologists across private and public healthcare sectors. She underwent multiple interventions including hair transplantation, topical minoxidil therapy, and experimental exosome injections without adequate diagnostic workup or blood testing. Despite these treatments, her condition showed no improvement, and she experienced significant psychosocial distress compounded by harsh communication from some physicians. Subsequently, she pursued DNA-guided intervention with nutrigenomics through a specialized trichologist, representing a paradigm shift toward precision medicine in hair loss management. This case highlights critical gaps in conventional diagnostic approaches, the importance of comprehensive metabolic and genetic assessment, and the potential of personalized genomic-guided interventions in chronic hair loss. The case underscores the necessity of patient-centered care, multidisciplinary collaboration, and compassionate communication in managing conditions with significant psychological burden.

Keywords: Hair loss, Qatar, Topical minoxidil therapy, DNA.

1. INTRODUCTION

Female pattern hair loss [FPHL] and chronic diffuse hair loss represent prevalent yet often inadequately managed dermatological conditions affecting millions of women worldwide [1]. The psychosocial impact of hair loss in women is profound, leading to depression, anxiety, damaged self-esteem, and impaired quality of life [2]. Despite the availability of FDA-approved treatments such as topical minoxidil, clinical outcomes remain highly variable, with response rates ranging from 30% to 60% in controlled trials [3]. This variability reflects the complex, multifactorial etiology of hair loss, involving genetic predisposition, hormonal influences, nutritional deficiencies, and metabolic dysregulation [4].

Recent advances in precision medicine have revealed that genetic polymorphisms significantly influence treatment response in androgenetic alopecia. Single nucleotide polymorphisms [SNPs] in genes encoding sulfotransferases [SULT1A1], 5α-reductase isoenzymes [SRD5A1, SRD5A2], and androgen receptors can predict therapeutic efficacy and guide personalized treatment selection [5–7]. Pharmacogenetic-guided therapy has demonstrated response rates exceeding 85%, substantially higher than conventional empirical approaches [7]. Furthermore, emerging evidence suggests that metabolic disruptions, including arginine insufficiency and oxidative stress, play critical roles in hair follicle miniaturization and impaired regeneration [8].

Despite these scientific advances, significant gaps persist in clinical practice. Many patients undergo multiple consultations and receive empirical treatments without comprehensive diagnostic evaluation, including hormonal assessment, nutritional screening, or genetic profiling [9]. This case illustrates the consequences of fragmented care and highlights the transformative potential of integrating precision medicine principles, including genomic-guided nutrigenomics, into routine trichological practice.

1.1 Case Presentation

A young woman from Qatar presented with a three-year history of severe, progressive diffuse hair fall. The onset was insidious, with gradual thinning affecting the entire scalp, leading to visible reduction in hair density and significant psychological distress. The

patient reported that the hair loss had profoundly affected her overall quality of life, consistent with the well-documented psychosocial burden of alopecia in young women [10].

Over the course of three years, the patient consulted eight different dermatologists across both private and public healthcare sectors in Qatar, seeking effective treatment for her condition. Despite multiple consultations, she did not receive a comprehensive diagnostic workup. Notably, adequate blood testing to assess hormonal status, nutritional deficiencies [including iron, vitamin D, and thyroid function], or metabolic parameters was not performed [11]. The absence of targeted history-taking regarding signs of hyperandrogenism, menstrual irregularities, dietary patterns, or family history of hair loss further limited diagnostic precision [11].

1.2 Clinical Course

1.2.1 Initial Interventions

Based on clinical examination alone, the patient was prescribed topical minoxidil, the only FDA-approved treatment for female pattern hair loss [3]. However, the treatment was initiated without consideration of potential genetic factors affecting minoxidil metabolism, such as polymorphisms in the SULT1A1 gene, which encodes the sulfotransferase enzyme responsible for converting minoxidil to its active form, minoxidil sulfate [12,13]. Genetic variants, particularly the TC genotype of rs1042028 in SULT1A1, are robust negative predictors of minoxidil response, with odds ratios as low as 0.09 [6,7].

Despite several months of topical minoxidil therapy, the patient experienced no improvement in hair density or reduction in hair shedding. The lack of response, rather than prompting comprehensive reassessment, led to escalation of interventions without adequate diagnostic clarification.

1.2.2 Procedural Interventions

The patient subsequently underwent hair transplantation, a surgical procedure typically reserved for patients with stable, well-defined pattern hair loss and adequate donor area density [14]. Hair transplantation aims to redistribute hair follicles from unaffected occipital regions to areas of low density [14]. However, in the context of ongoing, uncontrolled diffuse hair loss without established diagnosis or treatment of underlying metabolic or hormonal abnormalities, transplantation carries significant risk of poor graft survival and continued progression of hair loss in both recipient and donor areas [15].

In addition to transplantation, the patient received experimental exosome injections, a novel regenerative therapy with limited clinical validation and modest evidence for efficacy in hair loss disorders [16]. Exosome-based therapies are hypothesized to deliver growth factors and signaling molecules to hair follicles, but their use remains investigational, and standardized protocols are lacking [16].

1.2.3 Treatment Failure and Psychosocial Impact

Despite these multiple interventions such as topical minoxidil, hair transplantation, and exosome injections, the patient's hair loss showed no improvement. The continued progression of hair fall, combined with the physical and financial burden of unsuccessful treatments, exacerbated her psychological distress. Compounding this suffering, the patient reported experiencing harsh and dismissive language from some of the physicians she consulted. Such negative communication undermines the therapeutic relationship, increases patient anxiety, and contributes to feelings of hopelessness [17]. The psychosocial impact of hair loss is well-documented, with studies showing that women with alopecia experience anxiety, depression, social withdrawal, and stigmatization [2,10]. Compassionate, patient-centered communication is essential in managing conditions with significant psychological burden [17].

1.2.4 Transition to Precision Medicine Approach

Recognizing the failure of conventional approaches and seeking a more comprehensive evaluation, the patient consulted a specialized trichologist who employed a precision medicine framework. This approach integrated detailed clinical assessment, comprehensive laboratory evaluation, and DNA-guided nutrigenomic analysis. The trichologist conducted a thorough history, including assessment of dietary patterns, metabolic health, hormonal status, and family history of hair loss [5].

Comprehensive blood testing was performed to evaluate hormonal parameters [including androgens, thyroid function], nutritional status [iron stores, vitamin D, zinc, and other micronutrients], and metabolic markers [5]. Importantly, pharmacogenetic testing was conducted to identify genetic variants affecting drug metabolism and treatment response, including polymorphisms in SULT1A1, SRD5A1, SRD5A2, and androgen receptor genes [5].

Based on the genetic and metabolic profile, a personalized nutrigenomic intervention was designed. Nutrigenomics, the study of how genetic variation influences response to dietary components, enables tailored nutritional strategies to optimize metabolic pathways critical for hair follicle health [18]. Emerging evidence suggests that metabolic disruptions, such as arginine insufficiency due to downregulation of the arginine transporter SLC7A1 and upregulation of the catabolic enzyme ARG2, impair hair regeneration via oxidative stress and inactivation of mTOR signaling [8]. Localized metabolic correction through targeted

supplementation has shown therapeutic efficacy in preclinical models [8].

The precision-guided approach also incorporated consideration of the patient's genetic profile to avoid therapies predicted to be ineffective based on her genotype, thereby preventing further treatment failures and adverse effects[6,7]. This patient-centered strategy, integrating genomic data with customized nutritional and pharmacological interventions, represents a paradigm shift from empirical, trial-and-error treatment to evidence-based, individualized care [19] [see Figure 1].



Figure 1 . This figure presents a generalized clinical pathway illustrating a precision-based approach to hair loss management. It highlights the process of accurate diagnosis, integration of multidimensional patient factors, and tailored interventions designed to achieve optimized, individualized treatment outcomes.

2. DISCUSSION

2.1 Gaps in Conventional Care

This case illustrates several critical gaps in the conventional management of chronic hair loss. First, the absence of comprehensive diagnostic evaluation, including hormonal, nutritional, and metabolic assessment, represents a fundamental failure to identify treatable underlying causes. Blood tests to assess androgen levels, thyroid function, iron stores, and vitamin D are essential components of the diagnostic workup for hair loss, yet they were not performed despite multiple consultations. This omission reflects a broader pattern in clinical practice where hair loss is managed empirically without adequate investigation.

Second, the initiation of multiple treatments including invasive procedures such as hair transplantation without establishing a clear diagnosis or addressing underlying pathophysiology is problematic. Hair transplantation is most effective in patients with stable, well-characterized pattern hair loss and controlled underlying disease. In the context of active, diffuse hair loss of unclear etiology, transplantation is unlikely to succeed and may cause additional harm [15].

Third, the lack of consideration of pharmacogenetic factors in treatment selection represents a missed opportunity to optimize therapy. Genetic polymorphisms in drug-metabolizing enzymes and drug targets significantly influence treatment response [5–7]. For example, the TC genotype of rs1042028 in SULT1A1 is associated with poor response to minoxidil, finasteride, and dutasteride, with odds ratios ranging from 0.09 to 0.21 [5–7]. Similarly, the TT genotype of rs39848 in SRD5A1 predicts reduced efficacy of dutasteride [5–7]. Pharmacogenetic testing can identify patients unlikely to respond to specific therapies, enabling selection of alternative agents and avoiding futile treatments [19].

2.2 The Role of Precision Medicine

Precision medicine, defined as the tailoring of medical treatment to the individual characteristics of each patient, offers a transformative approach to hair loss management [19]. By integrating genetic, metabolic, and environmental data, precision medicine enables stratification of patients into subgroups with distinct pathophysiological mechanisms and treatment responses [19]. In the context of hair loss, precision medicine encompasses pharmacogenetic testing to guide drug selection, nutrigenomic analysis to optimize dietary interventions, and comprehensive metabolic profiling to identify and correct underlying deficiencies [5–7,18].

Pharmacogenetic-guided therapy has demonstrated substantial improvements in treatment outcomes. In a study of androgenetic alopecia patients stratified by SNP profiles, response rates ranged from 85.6% to 91.0%, significantly exceeding published benchmarks for empirical therapy [7]. The uniformly high response rates across different treatment pathways suggest that matching patients to therapies based on genetic profiles enhances efficacy and reduces inter-individual variability [5–7]. This approach also

minimizes adverse effects by avoiding drugs predicted to be ineffective or poorly tolerated [19].

Nutrigenomics represents another critical component of precision medicine in hair loss. Genetic variation influences the metabolism and utilization of nutrients essential for hair follicle function, including amino acids, vitamins, and trace elements [18]. For example, arginine metabolism is critical for hair regeneration, and disruption of arginine homeostasis due to genetic or acquired factors impairs follicular function via oxidative stress and mTOR pathway inactivation [8]. Targeted supplementation based on genetic and metabolic profiling can restore metabolic balance and support hair regrowth [8,18].

The integration of pharmacogenomics with customized formulations and nutrigenomic interventions represents a logical next step in personalized hair loss management, with potential to improve efficacy, safety, and adherence [19]. However, implementation of precision medicine faces barriers, including limited clinician training, reimbursement challenges, and the need for population-specific genetic data [20]. Overcoming these barriers requires institutional commitment, development of clinical decision support tools, and demonstration of cost-effectiveness [20].

2.3 Psychosocial Impact and Patient-Centered Care

The psychosocial impact of hair loss in women is profound and often underestimated by clinicians. Studies consistently demonstrate that women with alopecia experience significant reductions in quality of life, with elevated rates of depression, anxiety, social withdrawal, and impaired self-esteem [10]. Hair loss can lead to negative impacts on functioning, emotions, self-confidence, and interpersonal relationships, with some patients developing dysmorphophobia or affective disorders. The psychological burden is particularly severe in young women, for whom hair is closely tied to identity and femininity.

In this case, the patient's distress was compounded by harsh and dismissive communication from some physicians. Such negative interactions undermine trust, increase anxiety, and contribute to feelings of hopelessness and isolation [17]. Compassionate, empathetic communication is essential in managing conditions with significant psychological burden [17]. Clinicians should acknowledge the emotional impact of hair loss, validate patients' concerns, and provide realistic expectations regarding treatment outcomes [17].

Patient-centered care requires a multidisciplinary approach that addresses both the physical and psychological dimensions of hair loss. Dermatologists should collaborate with endocrinologists, nutritionists, mental health professionals, and specialized trichologists to provide comprehensive evaluation and management. Shared decision-making, in which patients are actively involved in treatment selection based on their preferences, values, and genetic profiles, enhances adherence and satisfaction. Standardized photography and trichoscopic evaluation are valuable tools for monitoring treatment response and facilitating communication between clinician and patient [21]. Visual documentation helps set realistic expectations and provides objective evidence of progress or lack thereof, supporting informed decision-making [21].

2.4 Multidisciplinary Approach and Clinical Flowchart

Effective management of chronic hair loss requires a structured, multidisciplinary approach that integrates clinical assessment, laboratory evaluation, genetic testing, and personalized treatment planning. Figure 2 presents a clinical flowchart illustrating the Biopsychosocial-Spiritual [BPSS] model for chronic hair fall management, emphasizing the importance of comprehensive patient evaluation, trichologist integration, and continuous feedback loops.

The BPSS model recognizes that hair loss is not merely a dermatological condition but a complex disorder with biological, psychological, social, and spiritual dimensions [see Figure 2]. Biological factors include genetic predisposition, hormonal imbalances, nutritional deficiencies, and metabolic dysregulation. Psychological factors encompass the emotional impact of hair loss, including anxiety, depression, and impaired self-esteem. Social factors include the stigma associated with hair loss and its effects on interpersonal relationships and social functioning. Spiritual factors relate to the patient's sense of identity, purpose, and well-being [see Figure 2].

A multidisciplinary team, including dermatologists, endocrinologists, nutritionists, genetic counselors, and mental health professionals, is essential to address these multiple dimensions. The trichologist, as a specialist in hair and scalp disorders, plays a central role in coordinating care, integrating genetic and metabolic data, and designing personalized treatment plans. Continuous feedback loops ensure that treatment is adjusted based on objective monitoring of hair density, shedding rates, and patient-reported outcomes.



Figure 2. This figure illustrates the integrative Biopsychosocial-Spiritual (BPSS) model applied to precision-based management of chronic hair fall.

2.5 Emerging Therapies and Future Directions

The landscape of hair loss treatment is rapidly evolving, with several emerging therapies showing promise. Janus kinase [JAK] inhibitors, initially developed for alopecia areata, have demonstrated efficacy in restoring hair growth by modulating immune signaling pathways [22]. However, limitations include high cost, potential side effects, and high relapse rates after discontinuation [22,23]. Continued research is needed to optimize dosing, identify predictors of response, and develop strategies for long-term maintenance [23].

Gene-based therapies, including RNA interference technologies such as small interfering RNAs [siRNAs] targeting androgen receptors, represent novel approaches to androgenetic alopecia [24]. These therapies aim to silence the androgen receptor gene locally, reducing sensitivity to dihydrotestosterone [DHT] without systemic side effects [24]. Early clinical trials have shown promising results, with improvements in hair density and patient-reported outcomes [24].

Metabolic correction strategies, such as targeted supplementation with arginine or inhibition of arginine-catabolizing enzymes, offer another avenue for intervention [8]. Preclinical studies have demonstrated that restoring arginine homeostasis can reverse oxidative stress, reactivate mTOR signaling, and promote hair regeneration [8]. Translation of these findings to clinical practice requires well-designed trials to establish efficacy, safety, and optimal dosing [8].

Multi-omics approaches, integrating genomics, transcriptomics, proteomics, and metabolomics, are providing unprecedented insights into the molecular mechanisms of hair loss [25]. These approaches enable identification of novel biomarkers for diagnosis, prognosis, and treatment response, paving the way for increasingly precise and effective therapies [25]. However, integration of multi-omics data into clinical practice requires robust bioinformatics infrastructure, clinical validation, and regulatory approval [25].

3. CONCLUSIONS

This case involving a young woman with chronic, treatment refractory hair loss underscores several persistent gaps within conventional diagnostic and therapeutic pathways. It highlights the consequences of incomplete clinical evaluation, particularly the lack of comprehensive endocrine, metabolic, and nutritional assessment, and demonstrates how these omissions can delay or obscure the true cause of hair loss. Equally important, the case illustrates the profound psychosocial burden experienced by patients and reinforces the need for compassionate, patient centered communication. Within trichology, this case further emphasizes the importance of adopting thorough, scientifically grounded assessment methods that align with modern standards of care. It also reinforces the value of a multidisciplinary strategy that integrates dermatology, endocrinology, nutrition, genetics, mental health, and advanced trichological practice to create a truly holistic model of care.

As precision medicine continues to evolve, the incorporation of genomic, metabolic, clinical, and

trichology driven data offers the potential to design increasingly individualized treatment strategies for chronic hair loss. However, realizing this potential requires addressing barriers related to clinician education, healthcare infrastructure, and financial reimbursement. Emerging economic evidence suggests that precision-based approaches may ultimately reduce healthcare costs by limiting adverse events and avoiding ineffective or unnecessary treatments.

The overarching goal of precision-based hair loss management in trichology is to align each patient with the most appropriate therapy based on their unique genetic, metabolic, and clinical profile, while simultaneously addressing the psychological and social dimensions of their condition. This case demonstrates that such an approach is not only scientifically robust but also essential for delivering compassionate, effective, and patient centered care to individuals suffering from chronic hair loss.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Data availability statement

The raw data supporting this article will be made available by the authors, without undue reservation.

Ethics statement

Written informed consent was obtained from the individual[s] for the publication of any potentially identifiable images or data included in this article. Written informed consent was obtained from the participant/patient[s] for the publication of this case report.

Author Contributions

N.A. conceived the idea, conducted the literature review, analyzed the findings, and wrote the manuscript. N.A. agrees to be accountable for all aspects of the work.

Funding

This report was entirely self-funded by the author. No external grants or financial support were received for the preparation of this work.

Acknowledgements

We extend our sincere gratitude to the Trichologist team for their invaluable contributions to the development of the treatment plan. Their expertise and commitment to high-quality hair restoration enriched the accuracy of this article. We also thank the individuals who shared their personal experiences, which helped illustrate the real-world impact of the clinic's services. The author further expresses her appreciation to the specialized endocrinologist whose guidance and collaboration were essential in shaping a holistic, multidisciplinary treatment approach.

REFERENCES

1. Olsen EA. Female pattern hair loss. J Am Acad Dermatol. 2001 Sep;45[3 Suppl]:S70-80. doi:10.1067/mjd.2001.117426 PubMed PMID: 11511856.
2. Ho CY, Chen JYF, Hsu WL, Yu S, Chen WC, Chiu SH, *et al.,* Female Pattern Hair Loss: An Overview with Focus on the Genetics. Genes. 2023 Jun 23;14[7]. doi:10.3390/genes14071326
3. Kanti V, Messenger A, Dobos G, Reygagne P, Finner A, Blumeyer A, *et al.,* Evidence-based [S3] guideline for the treatment of androgenetic alopecia in women and in men - short version. J Eur Acad Dermatol Venereol. 2018 Jan;32[1]:11–22. doi:10.1111/jdv.14624 PubMed PMID: 29178529.
4. Redler S, Messenger AG, Betz RC. Genetics and other factors in the aetiology of female pattern hair loss. Exp Dermatol. 2017 Jun;26[6]:510–7. doi:10.1111/exd.13373 PubMed PMID: 28453904.
5. Gaboardi H, Russo V, Vila-Vecilla L, Patel V, Souza GTD. 26-SNP Panel Aids Guiding Androgenetic Alopecia Therapy and Provides Insight into Mechanisms of Action. Cosmetics. 2025 Sep 2;12[5]. doi:10.3390/cosmetics12050190
6. Warner AW. Pharmacogenomics in clinical drug development and potential for alopecia areata. J Investig Dermatol Symp Proc. 2013 Dec;16[1]:S39-40. doi:10.1038/jidsymp.2013.12 PubMed PMID: 24326549.
7. Vila-Vecilla L, Russo V, Souza GT de. Genomic Markers and Personalized Medicine in Androgenetic Alopecia: A Comprehensive Review. Cosmetics. 2024 Aug 27;11[5]. doi:10.3390/cosmetics11050148
8. Duan S, Li G, Chu Y, Zhang J, Yang L, Zhang Y, *et al.,* Arginine Metabolic Disruption Impairs Hair Regeneration via ROS-Mediated Inactivation of mTOR Signaling in Androgenetic Alopecia. Adv Sci [Weinh]. 2025 Oct;12[40]:e04579. doi:10.1002/advs.202504579 PubMed PMID: 40776528; PubMed Central PMCID: PMC12561341.
9. Ntshingila S, Oputu O, Arowolo AT, Khumalo NP. Androgenetic alopecia: An update. JAAD Int. 2023 Dec; 13:150–8. doi: 10.1016/j.jdin.2023.07.005

PubMed PMID: 37823040; PubMed Central PMCID: PMC10562178.
10. Ho CY, Wu CY, Chen JYF, Wu CY. Clinical and Genetic Aspects of Alopecia Areata: A Cutting-Edge Review. Genes [Basel]. 2023 Jun 28;14[7]:1362. doi:10.3390/genes14071362 PubMed PMID: 37510267; PubMed Central PMCID: PMC10379312.
11. Carmina E, Azziz R, Bergfeld W, Escobar-Morreale HF, Futterweit W, Huddleston H, *et al.,* Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee. J Clin Endocrinol Metab. 2019 Jul 1;104[7]:2875–91. doi:10.1210/jc.2018-02548 PubMed PMID: 30785992.
12. Whiting DA. Possible mechanisms of miniaturization during androgenetic alopecia or pattern hair loss. J Am Acad Dermatol. 2001 Sep;45[3 Suppl]:S81-86. doi:10.1067/mjd.2001.117428 PubMed PMID: 11511857.
13. Inui S, Itami S. Molecular basis of androgenetic alopecia: From androgen to paracrine mediators through dermal papilla. J Dermatol Sci. 2011 Jan;61[1]:1–6. doi: 10.1016/j.jdermsci.2010.10.015 PubMed PMID: 21167691.
14. Olsen EA. The midline part: an important physical clue to the clinical diagnosis of androgenetic alopecia in women. J Am Acad Dermatol. 1999 Jan;40[1]:106–9. doi:10.1016/s0190-9622[99]70539-6 PubMed PMID: 9922024.
15. Martinez-Lopez A, Montero-Vilchez T, Sierra-Sánchez Á, Molina-Leyva A, Arias-Santiago S. Advanced Medical Therapies in the Management of Non-Scarring Alopecia: Areata and Androgenic Alopecia. Int J Mol Sci. 2020 Nov 9;21[21]:8390. doi:10.3390/ijms21218390 PubMed PMID: 33182308; PubMed Central PMCID: PMC7664905.
16. Yilmaz DN, Onluturk Aydogan O, Kori M, Aydin B, Rahman MdR, Moni MA, *et al.,* Prospects of integrated multi-omics-driven biomarkers for efficient hair loss therapy from systems biology perspective. Gene Reports. 2022 Sep 1; 28:101657. doi: 10.1016/j.genrep.2022.101657
17. Gupta AK, Carviel J, Abramovits W. Treating Alopecia Areata: Current Practices Versus New Directions. Am J Clin Dermatol. 2017 Feb;18[1]:67–75. doi:10.1007/s40257-016-0230-4 PubMed PMID: 27770310.
18. Palou A. From nutrigenomics to personalised nutrition. Genes Nutr. 2007 Oct;2[1]:5–7. doi:10.1007/s12263-007-0022-9 PubMed PMID: 18850129; PubMed Central PMCID: PMC2474919.
19. Basmanav FB, Betz RC. Translational impact of omics studies in alopecia areata: recent advances and future perspectives. Expert Rev Clin Immunol. 2022 Aug;18[8]:845–57. doi:10.1080/1744666X.2022.2096590 PubMed PMID: 35770930.
20. Seymour CW, Gomez H, Chang CCH, Clermont G, Kellum JA, Kennedy J, *et al.,* Precision medicine for all? Challenges and opportunities for a precision medicine approach to critical illness. Crit Care. 2017 Oct 18;21[1]:257. doi:10.1186/s13054-017-1836-5 PubMed PMID: 29047353; PubMed Central PMCID: PMC5648512.
21. Manabe M, Tsuboi R, Itami S, Osada SI, Amoh Y, Ito T, *et al.,* Guidelines for the diagnosis and treatment of male-pattern and female-pattern hair loss, 2017 version. J Dermatol. 2018 Sep;45[9]:1031–43. doi:10.1111/1346-8138.14470 PubMed PMID: 29863806.
22. Wang ECE, Christiano AM. The Changing Landscape of Alopecia Areata: The Translational Landscape. Adv Ther. 2017 Jul;34[7]:1586–93. doi:10.1007/s12325-017-0540-9 PubMed PMID: 28646392; PubMed Central PMCID: PMC5504204.
23. Peterle L, Sanfilippo S, Borgia F, Cicero N, Gangemi S. Alopecia Areata: A Review of the Role of Oxidative Stress, Possible Biomarkers, and Potential Novel Therapeutic Approaches. Antioxidants [Basel]. 2023 Jan 6;12[1]:135. doi:10.3390/antiox12010135 PubMed PMID: 36670997; PubMed Central PMCID: PMC9854963.
24. Yun SI, Lee SK, Goh EA, Kwon OS, Choi W, Kim J, *et al.,* Weekly treatment with SAMiRNA targeting the androgen receptor ameliorates androgenetic alopecia. Sci Rep. 2022 Jan 31;12[1]:1607. doi:10.1038/s41598-022-05544-w PubMed PMID: 35102171; PubMed Central PMCID: PMC8803970.
25. Li Y, Dong T, Wan S, Xiong R, Jin S, Dai Y, *et al.,* Application of multi-omics techniques to androgenetic alopecia: Current status and perspectives. Comput Struct Biotechnol J. 2024 Jun 20; 23:2623–36. doi: 10.1016/j.csbj.2024.06.026 PubMed PMID: 39021583; PubMed Central PMCID: PMC11253216.